Red cell aplasia due to parvovirus B19 in a patient treated with alemtuzumab

被引：17

作者：

Crowley, B ^{[1
]}

Woodcock, B

机构：

[1] Univ Hosp Aintree, Liverpool Publ Hlth Lab, Liverpool, Merseyside, England

[2] Univ Hosp Aintree, Dept Haematol, Liverpool, Merseyside, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 119卷 / 01期

关键词：

alemtuzumab; humoral immunodeficiency; parvovirus B19; red cell aplasia; intravenous immunoglobulin;

D O I：

10.1046/j.1365-2141.2002.37668.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：279 / 280

页数：2

共 5 条

[1]

ABKOWITZ JL, 1993, CLIN RES, V41, P393

[2] High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H [J].

Dearden, CE ;

Matutes, E ;

Cazin, B ;

Tjonnfjord, GE ;

Parreira, A ;

Nomdedeu, B ;

Leoni, P ;

Clark, FJ ;

Radia, D ;

Rassam, SMB ;

Roques, T ;

Ketterer, N ;

Brito-Babapulle, V ;

Dyer, MJS ;

Catovsky, D .

BLOOD, 2001, 98 (06) :1721-1726

[3] PARVOVIRUS-B19 FOR THE HEMATOLOGIST [J].

HARRIS, JW .

AMERICAN JOURNAL OF HEMATOLOGY, 1992, 39 (02) :119-130

[4] CHRONIC BONE-MARROW FAILURE DUE TO PERSISTENT B19-PARVOVIRUS INFECTION [J].

KURTZMAN, GJ ;

OZAWA, K ;

COHEN, B ;

HANSON, G ;

OSEAS, R ;

YOUNG, NS .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (05) :287-294

[5] CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas:: A phase II multicenter study [J].

Lundin, J ;

Österborg, A ;

Brittinger, G ;

Crowther, D ;

Dombret, H ;

Engert, A ;

Epenetos, A ;

Gisselbrecht, C ;

Huhn, D ;

Jaeger, U ;

Thomas, J ;

Marcus, R ;

Nissen, N ;

Poynton, C ;

Rankin, E ;

Stahel, R ;

Uppenkamp, M ;

Willemze, R ;

Mellstedt, H .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3257-3263

← 1 →